Literature DB >> 10487578

Optimization of stereotactically-guided conformal treatment planning of sellar and parasellar tumors, based on normal brain dose volume histograms.

J R Perks1, R Jalali, V P Cosgrove, E J Adams, S F Shepherd, A P Warrington, M Brada.   

Abstract

PURPOSE: To investigate the optimal treatment plan for stereotactically-guided conformal radiotherapy (SCRT) of sellar and parasellar lesions, with respect to sparing normal brain tissue, in the context of routine treatment delivery, based on dose volume histogram analysis. METHODS AND MATERIALS: Computed tomography (CT) data sets for 8 patients with sellar- and parasellar-based tumors (6 pituitary adenomas and 2 meningiomas) have been used in this study. Treatment plans were prepared for 3-coplanar and 3-, 4-, 6-, and 30-noncoplanar-field arrangements to obtain 95% isodose coverage of the planning target volume (PTV) for each plan. Conformal shaping was achieved by customized blocks generated with the beams eye view (BEV) facility. Dose volume histograms (DVH) were calculated for the normal brain (excluding the PTV), and comparisons made for normal tissue sparing for all treatment plans at > or =80%, > or =60%, and > or =40% of the prescribed dose.
RESULTS: The mean volume of normal brain receiving > or =80% and > or =60% of the prescribed dose decreased by 22.3% (range 14.8-35.1%, standard deviation sigma = 7.5%) and 47.6% (range 25.8-69.1%, sigma = 13.2%), respectively, with a 4-field noncoplanar technique when compared with a conventional 3-field coplanar technique. Adding 2 further fields, from 4-noncoplanar to 6-noncoplanar fields reduced the mean normal brain volume receiving > or =80% of the prescribed dose by a further 4.1% (range -6.5-11.8%, sigma = 6.4%), and the volume receiving > or =60% by 3.3% (range -5.5-12.2%, sigma = 5.4%), neither of which were statistically significant. Each case must be considered individually however, as a wide range is seen in the volume spared when increasing the number of fields from 4 to 6. Comparing the 4- and 6-field noncoplanar techniques to a 30-field conformal field approach (simulating a dynamic arc plan) revealed near-equivalent normal tissue sparing.
CONCLUSION: Four to six widely spaced, fixed-conformal fields provide the optimum class solution for the treatment of sellar and parasellar lesions, both in terms of normal brain tissue sparing and providing a relatively straightforward patient setup. Increasing the number of fields did not result in further significant sparing, with no clear benefit from techniques approaching dynamic conformal radiotherapy in the cases examined.

Entities:  

Mesh:

Year:  1999        PMID: 10487578     DOI: 10.1016/s0360-3016(99)00156-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  5 in total

1.  Linear accelerator-based radiosurgery for multiple arteriovenous malformations: case report.

Authors:  Julian R Perks; Claus Yang; Kamran Sahrakar; Conrad Pappas; Jonathan Hartman; H Kubo; Allan Chen
Journal:  AJNR Am J Neuroradiol       Date:  2005-08       Impact factor: 3.825

2.  Radiotherapy for craniopharyngioma.

Authors:  Ajay Aggarwal; Naomi Fersht; Michael Brada
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

Review 3.  Modern techniques for pituitary radiotherapy.

Authors:  G Minniti; D C Gilbert; M Brada
Journal:  Rev Endocr Metab Disord       Date:  2009-06       Impact factor: 6.514

4.  Prospective assessment of activities of daily living using modified Barthel's Index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy.

Authors:  Rakesh Jalali; Debnarayan Dutta; Rashmi Kamble; Tejpal Gupta; Anusheel Munshi; Rajiv Sarin; Ketayun Dinshaw
Journal:  J Neurooncol       Date:  2008-08-14       Impact factor: 4.130

5.  Commissioning and implementation of a stereotactic conformal radiotherapy technique using a general-purpose planning system.

Authors:  M Amin Mosleh-Shirazi; Vibeke N Hansen; Peter J Childs; Alan P Warrington; Frank H Saran
Journal:  J Appl Clin Med Phys       Date:  2004-07-01       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.